{"id":8831,"date":"2024-01-23T09:00:11","date_gmt":"2024-01-23T14:00:11","guid":{"rendered":"https:\/\/www.bluerocktx.com\/?p=8831"},"modified":"2024-04-11T11:17:30","modified_gmt":"2024-04-11T15:17:30","slug":"bluerock-therapeutics-exercises-exclusive-option-to-license-ipsc-cell-therapy-candidate-opct-001-for-treating-primary-photoreceptor-diseases-from-fujifilm-cellular-dynamics-and-opsis-therapeutics","status":"publish","type":"post","link":"https:\/\/www.bluerocktx.com\/bluerock-therapeutics-exercises-exclusive-option-to-license-ipsc-cell-therapy-candidate-opct-001-for-treating-primary-photoreceptor-diseases-from-fujifilm-cellular-dynamics-and-opsis-therapeutics\/","title":{"rendered":"BlueRock Therapeutics exercises exclusive option to license iPSC cell therapy candidate OpCT-001 for treating Primary Photoreceptor Diseases from FUJIFILM Cellular Dynamics and Opsis Therapeutics"},"content":{"rendered":"<ul>\n<li data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"3\" data-list-defn-props=\"{&quot;335551671&quot;:26,&quot;335552541&quot;:1,&quot;335559684&quot;:-2,&quot;335559685&quot;:720,&quot;335559991&quot;:360,&quot;469769226&quot;:&quot;Symbol&quot;,&quot;469769242&quot;:[8226],&quot;469777803&quot;:&quot;left&quot;,&quot;469777804&quot;:&quot;\uf0b7&quot;,&quot;469777815&quot;:&quot;hybridMultilevel&quot;}\" aria-setsize=\"-1\" data-aria-posinset=\"26\" data-aria-level=\"1\"><span data-contrast=\"auto\">First iPSC therapy candidate to be licensed from the strategic R&amp;D collaboration forged between BlueRock, FUJIFILM Cellular Dynamics, and Opsis Therapeutics in 2021<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/li>\n<li data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"3\" data-list-defn-props=\"{&quot;335551671&quot;:26,&quot;335552541&quot;:1,&quot;335559684&quot;:-2,&quot;335559685&quot;:720,&quot;335559991&quot;:360,&quot;469769226&quot;:&quot;Symbol&quot;,&quot;469769242&quot;:[8226],&quot;469777803&quot;:&quot;left&quot;,&quot;469777804&quot;:&quot;\uf0b7&quot;,&quot;469777815&quot;:&quot;hybridMultilevel&quot;}\" aria-setsize=\"-1\" data-aria-posinset=\"26\" data-aria-level=\"1\"><span data-contrast=\"auto\">Primary photoreceptor diseases affect the structure and function of the photoreceptor cells in the retina, leading to irreversible vision loss in children and adults\u00a0<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/li>\n<li data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"3\" data-list-defn-props=\"{&quot;335551671&quot;:26,&quot;335552541&quot;:1,&quot;335559684&quot;:-2,&quot;335559685&quot;:720,&quot;335559991&quot;:360,&quot;469769226&quot;:&quot;Symbol&quot;,&quot;469769242&quot;:[8226],&quot;469777803&quot;:&quot;left&quot;,&quot;469777804&quot;:&quot;\uf0b7&quot;,&quot;469777815&quot;:&quot;hybridMultilevel&quot;}\" aria-setsize=\"-1\" data-aria-posinset=\"26\" data-aria-level=\"1\"><span data-contrast=\"auto\">IND filing for OpCT-001 is planned for 2024<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/li>\n<\/ul>\n<p><b><span data-contrast=\"auto\">Cambridge, MA USA, January<\/span><\/b> <b><span data-contrast=\"none\">23, <\/span><\/b><b><span data-contrast=\"auto\">2024<\/span><\/b><span data-contrast=\"auto\"> &#8211; <\/span><span data-contrast=\"auto\">BlueRock Therapeutics LP, a clinical stage cell therapy company and wholly owned, independently operated subsidiary of Bayer AG, announced today that it has exercised its option to exclusively license OpCT-001, an induced pluripotent stem cell (iPSC) derived cell therapy candidate for the treatment of primary photoreceptor diseases, from <\/span><span data-contrast=\"auto\">FUJIFILM Cellular Dynamics and Opsis Therapeutics<\/span><span data-contrast=\"auto\">. OpCT-001 is the lead cell therapy candidate being developed under the strategic R&amp;D collaboration between BlueRock,<\/span><span data-contrast=\"auto\"> FUJIFILM Cellular Dynamics,<\/span><span data-contrast=\"auto\"> and Opsis Therapeutics that was forged in 2021. Under the terms of the agreement <\/span><span data-contrast=\"auto\">FUJIFILM Cellular Dynamics,<\/span><span data-contrast=\"auto\"> and Opsis Therapeutics<\/span> <span data-contrast=\"auto\">receive an undisclosed license fee and are eligible to receive <\/span><span data-contrast=\"auto\">payments upon achievement of certain development and commercial milestones.\u00a0<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">\u201cWe believe that cell therapy has great potential for restoring vision in patients who are living with retinal diseases,\u201d said Ahmed Enayetallah, Senior Vice President and Head of Development at BlueRock Therapeutics. \u201cOur collaboration with the <\/span><span data-contrast=\"auto\">FUJIFILM Cellular Dynamics and<\/span><span data-contrast=\"auto\"> Opsis Therapeutics team has allowed us to <\/span><span data-contrast=\"auto\">execute important IND-enabling activities, <\/span><span data-contrast=\"auto\">and we are excited to advance OpCT-001 toward the clinic, with an IND filing planned for this year.\u201d<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">Primary photoreceptor diseases are a subgroup of inherited retinal disorders that includes retinitis pigmentosa and cone rod dystrophies. These diseases affect the structure and function of the photoreceptor cells in the retina, leading to irreversible vision loss in both children and adults. No treatment options currently exist for this patient population. OpCT-001 aims to restore vision loss caused by these diseases by replacing degenerated tissue in the retina with functional cells.<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/p>\n<p><b><span data-contrast=\"auto\">About BlueRock Therapeutics LP<\/span><\/b><span data-contrast=\"auto\">\u202f<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559738&quot;:0,&quot;335559739&quot;:0}\"><br \/>\n<\/span><span data-contrast=\"auto\">BlueRock Therapeutics LP is a clinical stage cell therapy company focused on creating cellular medicines to reverse devastating diseases. We are harnessing the power of cell therapy to create a pipeline of new medicines for patients suffering from neurological, cardiovascular, immunological, and ophthalmic diseases. Our lead clinical program, bemdaneprocel, (BRT-DA01) is in Phase I clinical trials for Parkinson\u2019s disease. We were founded in 2016 as a joint venture of Versant Ventures and Leaps by Bayer, the impact investing arm of Bayer AG that invests in paradigm-shifting breakthrough innovation. In late 2019, BlueRock became a wholly owned, independently operated subsidiary of Bayer AG as a cornerstone of its newly formed Cell &amp; Gene Therapy platform. Our culture is defined by the courage to persist regardless of the challenge, the urgency to transform medicine and deliver hope, integrity guided by mission, and community-mindedness with the understanding that we are all part of something bigger than ourselves. For more information, visit <\/span><span data-contrast=\"none\"><a href=\"https:\/\/www.bluerocktx.com\">www.bluerocktx.com<\/a>.<\/span><span data-contrast=\"auto\">\u202f\u202f\u202f<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559738&quot;:0,&quot;335559739&quot;:0}\">\u00a0<\/span><\/p>\n<p>Follow us on\u00a0<a href=\"https:\/\/www.linkedin.com\/company\/bluerocktx\/\" target=\"_blank\" rel=\"noopener\">LinkedIn<\/a><\/p>\n<p><b><span data-contrast=\"none\">About Bayer<\/span><\/b><br \/>\n<span data-contrast=\"none\">Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2022, the Group employed around 101,000 people and had sales of 50.7 billion euros. R&amp;D expenses before special items amounted to 6.2 billion euros. For more information, go to\u202f<\/span><a href=\"http:\/\/www.bayer.com\/\">www.bayer.com<\/a><span data-contrast=\"none\">.<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559738&quot;:180,&quot;335559739&quot;:180}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"none\">Find more information at\u202f<\/span><a href=\"https:\/\/pharma.bayer.com\/\">https:\/\/pharma.bayer.com<\/a><br \/>\nFollow us on Facebook:\u202f<a href=\"http:\/\/www.facebook.com\/bayer\">http:\/\/www.facebook.com\/bayer<\/a><\/p>\n<p><b><span data-contrast=\"auto\">Forward-Looking Statements\u00a0<\/span><\/b><span data-ccp-props=\"{}\"><br \/>\n<\/span><span data-contrast=\"auto\">Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as \u201canticipate,\u201d \u201cbelieve,\u201d \u201cforecast,\u201d \u201cestimate,\u201d \u201cplan,\u201d and \u201cintend,\u201d among others. These forward-looking statements are based on BlueRock\u2019s current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, the initiation, timing, progress, activities, goals and reporting of results of any preclinical programs and clinical trials and research and development programs, the potential benefits, timing and future operation of the agreements with FUJIFILM Cellular Dynamics and Opsis Therapeutics, the ability to advance therapies into, and successfully initiate, enroll and complete clinical trials, the potential clinical utility of product candidates, the regulatory pathway of, and the timing or likelihood of any regulatory filings and approvals for, any product candidates, and the ability to, and extent of, potentially commercializing any product candidate, are forward looking. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Except as expressly required by law, BlueRock does not undertake an obligation to update or revise any forward-looking statement. All of BlueRock\u2019s forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date hereof.<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/p>\n<p><b><span data-contrast=\"auto\">Media Contact<\/span><\/b><span data-ccp-props=\"{}\"><br \/>\n<\/span><span data-contrast=\"auto\">Jeff Lockwood<\/span><span data-ccp-props=\"{}\"><br \/>\n<\/span><span data-contrast=\"auto\">Vice President, Communications<\/span><span data-ccp-props=\"{}\"><br \/>\n<\/span>p. 617 510 6997<br \/>\n<span data-contrast=\"auto\">e. <a href=\"mailto:jlockwood@bluerocktx.com\">jlockwood@bluerocktx.com<\/a>\u00a0<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>First iPSC therapy candidate to be licensed from the strategic R&amp;D collaboration forged between BlueRock, FUJIFILM Cellular Dynamics, and Opsis Therapeutics in 2021\u00a0 Primary photoreceptor diseases affect the structure and function of the photoreceptor cells in the retina, leading to irreversible vision loss in [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":8835,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[45],"tags":[52,58],"class_list":["post-8831","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-press-releases","tag-announcement","tag-ophthalmology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v23.4 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>BlueRock Therapeutics exercises exclusive option to license iPSC cell therapy candidate OpCT-001 for treating Primary Photoreceptor Diseases from FUJIFILM Cellular Dynamics and Opsis Therapeutics - BlueRock Therapeutics LP<\/title>\n<meta name=\"description\" content=\"First iPSC therapy candidate to be licensed from the strategic R&amp;D collaboration forged between BlueRock, FUJIFILM Cellular Dynamics, and Opsis Therapeutics in 2021\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.bluerocktx.com\/bluerock-therapeutics-exercises-exclusive-option-to-license-ipsc-cell-therapy-candidate-opct-001-for-treating-primary-photoreceptor-diseases-from-fujifilm-cellular-dynamics-and-opsis-therapeutics\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BlueRock Therapeutics exercises exclusive option to license iPSC cell therapy candidate OpCT-001 for treating Primary Photoreceptor Diseases from FUJIFILM Cellular Dynamics and Opsis Therapeutics - BlueRock Therapeutics LP\" \/>\n<meta property=\"og:description\" content=\"First iPSC therapy candidate to be licensed from the strategic R&amp;D collaboration forged between BlueRock, FUJIFILM Cellular Dynamics, and Opsis Therapeutics in 2021\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.bluerocktx.com\/bluerock-therapeutics-exercises-exclusive-option-to-license-ipsc-cell-therapy-candidate-opct-001-for-treating-primary-photoreceptor-diseases-from-fujifilm-cellular-dynamics-and-opsis-therapeutics\/\" \/>\n<meta property=\"og:site_name\" content=\"BlueRock Therapeutics LP\" \/>\n<meta property=\"article:published_time\" content=\"2024-01-23T14:00:11+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-04-11T15:17:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.bluerocktx.com\/wp-content\/uploads\/2024\/01\/WEBPART-OPSIS-ANNOUNCE.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1000\" \/>\n\t<meta property=\"og:image:height\" content=\"900\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"BlueRock Therapeutics\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"BlueRock Therapeutics\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.bluerocktx.com\/bluerock-therapeutics-exercises-exclusive-option-to-license-ipsc-cell-therapy-candidate-opct-001-for-treating-primary-photoreceptor-diseases-from-fujifilm-cellular-dynamics-and-opsis-therapeutics\/\",\"url\":\"https:\/\/www.bluerocktx.com\/bluerock-therapeutics-exercises-exclusive-option-to-license-ipsc-cell-therapy-candidate-opct-001-for-treating-primary-photoreceptor-diseases-from-fujifilm-cellular-dynamics-and-opsis-therapeutics\/\",\"name\":\"BlueRock Therapeutics exercises exclusive option to license iPSC cell therapy candidate OpCT-001 for treating Primary Photoreceptor Diseases from FUJIFILM Cellular Dynamics and Opsis Therapeutics - BlueRock Therapeutics LP\",\"isPartOf\":{\"@id\":\"https:\/\/www.bluerocktx.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.bluerocktx.com\/bluerock-therapeutics-exercises-exclusive-option-to-license-ipsc-cell-therapy-candidate-opct-001-for-treating-primary-photoreceptor-diseases-from-fujifilm-cellular-dynamics-and-opsis-therapeutics\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.bluerocktx.com\/bluerock-therapeutics-exercises-exclusive-option-to-license-ipsc-cell-therapy-candidate-opct-001-for-treating-primary-photoreceptor-diseases-from-fujifilm-cellular-dynamics-and-opsis-therapeutics\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.bluerocktx.com\/wp-content\/uploads\/2024\/01\/WEBPART-OPSIS-ANNOUNCE.jpg\",\"datePublished\":\"2024-01-23T14:00:11+00:00\",\"dateModified\":\"2024-04-11T15:17:30+00:00\",\"author\":{\"@id\":\"https:\/\/www.bluerocktx.com\/#\/schema\/person\/7bce67a9ee8dcf888329288a28761057\"},\"description\":\"First iPSC therapy candidate to be licensed from the strategic R&D collaboration forged between BlueRock, FUJIFILM Cellular Dynamics, and Opsis Therapeutics in 2021\",\"breadcrumb\":{\"@id\":\"https:\/\/www.bluerocktx.com\/bluerock-therapeutics-exercises-exclusive-option-to-license-ipsc-cell-therapy-candidate-opct-001-for-treating-primary-photoreceptor-diseases-from-fujifilm-cellular-dynamics-and-opsis-therapeutics\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.bluerocktx.com\/bluerock-therapeutics-exercises-exclusive-option-to-license-ipsc-cell-therapy-candidate-opct-001-for-treating-primary-photoreceptor-diseases-from-fujifilm-cellular-dynamics-and-opsis-therapeutics\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.bluerocktx.com\/bluerock-therapeutics-exercises-exclusive-option-to-license-ipsc-cell-therapy-candidate-opct-001-for-treating-primary-photoreceptor-diseases-from-fujifilm-cellular-dynamics-and-opsis-therapeutics\/#primaryimage\",\"url\":\"https:\/\/www.bluerocktx.com\/wp-content\/uploads\/2024\/01\/WEBPART-OPSIS-ANNOUNCE.jpg\",\"contentUrl\":\"https:\/\/www.bluerocktx.com\/wp-content\/uploads\/2024\/01\/WEBPART-OPSIS-ANNOUNCE.jpg\",\"width\":1000,\"height\":900},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.bluerocktx.com\/bluerock-therapeutics-exercises-exclusive-option-to-license-ipsc-cell-therapy-candidate-opct-001-for-treating-primary-photoreceptor-diseases-from-fujifilm-cellular-dynamics-and-opsis-therapeutics\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.bluerocktx.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BlueRock Therapeutics exercises exclusive option to license iPSC cell therapy candidate OpCT-001 for treating Primary Photoreceptor Diseases from FUJIFILM Cellular Dynamics and Opsis Therapeutics\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.bluerocktx.com\/#website\",\"url\":\"https:\/\/www.bluerocktx.com\/\",\"name\":\"BlueRock Therapeutics LP\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.bluerocktx.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.bluerocktx.com\/#\/schema\/person\/7bce67a9ee8dcf888329288a28761057\",\"name\":\"BlueRock Therapeutics\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.bluerocktx.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/154b53ac9f1feafa6f14d0efa17a4fdb?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/154b53ac9f1feafa6f14d0efa17a4fdb?s=96&d=mm&r=g\",\"caption\":\"BlueRock Therapeutics\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BlueRock Therapeutics exercises exclusive option to license iPSC cell therapy candidate OpCT-001 for treating Primary Photoreceptor Diseases from FUJIFILM Cellular Dynamics and Opsis Therapeutics - BlueRock Therapeutics LP","description":"First iPSC therapy candidate to be licensed from the strategic R&D collaboration forged between BlueRock, FUJIFILM Cellular Dynamics, and Opsis Therapeutics in 2021","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.bluerocktx.com\/bluerock-therapeutics-exercises-exclusive-option-to-license-ipsc-cell-therapy-candidate-opct-001-for-treating-primary-photoreceptor-diseases-from-fujifilm-cellular-dynamics-and-opsis-therapeutics\/","og_locale":"en_US","og_type":"article","og_title":"BlueRock Therapeutics exercises exclusive option to license iPSC cell therapy candidate OpCT-001 for treating Primary Photoreceptor Diseases from FUJIFILM Cellular Dynamics and Opsis Therapeutics - BlueRock Therapeutics LP","og_description":"First iPSC therapy candidate to be licensed from the strategic R&D collaboration forged between BlueRock, FUJIFILM Cellular Dynamics, and Opsis Therapeutics in 2021","og_url":"https:\/\/www.bluerocktx.com\/bluerock-therapeutics-exercises-exclusive-option-to-license-ipsc-cell-therapy-candidate-opct-001-for-treating-primary-photoreceptor-diseases-from-fujifilm-cellular-dynamics-and-opsis-therapeutics\/","og_site_name":"BlueRock Therapeutics LP","article_published_time":"2024-01-23T14:00:11+00:00","article_modified_time":"2024-04-11T15:17:30+00:00","og_image":[{"width":1000,"height":900,"url":"https:\/\/www.bluerocktx.com\/wp-content\/uploads\/2024\/01\/WEBPART-OPSIS-ANNOUNCE.jpg","type":"image\/jpeg"}],"author":"BlueRock Therapeutics","twitter_card":"summary_large_image","twitter_misc":{"Written by":"BlueRock Therapeutics","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.bluerocktx.com\/bluerock-therapeutics-exercises-exclusive-option-to-license-ipsc-cell-therapy-candidate-opct-001-for-treating-primary-photoreceptor-diseases-from-fujifilm-cellular-dynamics-and-opsis-therapeutics\/","url":"https:\/\/www.bluerocktx.com\/bluerock-therapeutics-exercises-exclusive-option-to-license-ipsc-cell-therapy-candidate-opct-001-for-treating-primary-photoreceptor-diseases-from-fujifilm-cellular-dynamics-and-opsis-therapeutics\/","name":"BlueRock Therapeutics exercises exclusive option to license iPSC cell therapy candidate OpCT-001 for treating Primary Photoreceptor Diseases from FUJIFILM Cellular Dynamics and Opsis Therapeutics - BlueRock Therapeutics LP","isPartOf":{"@id":"https:\/\/www.bluerocktx.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.bluerocktx.com\/bluerock-therapeutics-exercises-exclusive-option-to-license-ipsc-cell-therapy-candidate-opct-001-for-treating-primary-photoreceptor-diseases-from-fujifilm-cellular-dynamics-and-opsis-therapeutics\/#primaryimage"},"image":{"@id":"https:\/\/www.bluerocktx.com\/bluerock-therapeutics-exercises-exclusive-option-to-license-ipsc-cell-therapy-candidate-opct-001-for-treating-primary-photoreceptor-diseases-from-fujifilm-cellular-dynamics-and-opsis-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/www.bluerocktx.com\/wp-content\/uploads\/2024\/01\/WEBPART-OPSIS-ANNOUNCE.jpg","datePublished":"2024-01-23T14:00:11+00:00","dateModified":"2024-04-11T15:17:30+00:00","author":{"@id":"https:\/\/www.bluerocktx.com\/#\/schema\/person\/7bce67a9ee8dcf888329288a28761057"},"description":"First iPSC therapy candidate to be licensed from the strategic R&D collaboration forged between BlueRock, FUJIFILM Cellular Dynamics, and Opsis Therapeutics in 2021","breadcrumb":{"@id":"https:\/\/www.bluerocktx.com\/bluerock-therapeutics-exercises-exclusive-option-to-license-ipsc-cell-therapy-candidate-opct-001-for-treating-primary-photoreceptor-diseases-from-fujifilm-cellular-dynamics-and-opsis-therapeutics\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.bluerocktx.com\/bluerock-therapeutics-exercises-exclusive-option-to-license-ipsc-cell-therapy-candidate-opct-001-for-treating-primary-photoreceptor-diseases-from-fujifilm-cellular-dynamics-and-opsis-therapeutics\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.bluerocktx.com\/bluerock-therapeutics-exercises-exclusive-option-to-license-ipsc-cell-therapy-candidate-opct-001-for-treating-primary-photoreceptor-diseases-from-fujifilm-cellular-dynamics-and-opsis-therapeutics\/#primaryimage","url":"https:\/\/www.bluerocktx.com\/wp-content\/uploads\/2024\/01\/WEBPART-OPSIS-ANNOUNCE.jpg","contentUrl":"https:\/\/www.bluerocktx.com\/wp-content\/uploads\/2024\/01\/WEBPART-OPSIS-ANNOUNCE.jpg","width":1000,"height":900},{"@type":"BreadcrumbList","@id":"https:\/\/www.bluerocktx.com\/bluerock-therapeutics-exercises-exclusive-option-to-license-ipsc-cell-therapy-candidate-opct-001-for-treating-primary-photoreceptor-diseases-from-fujifilm-cellular-dynamics-and-opsis-therapeutics\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.bluerocktx.com\/"},{"@type":"ListItem","position":2,"name":"BlueRock Therapeutics exercises exclusive option to license iPSC cell therapy candidate OpCT-001 for treating Primary Photoreceptor Diseases from FUJIFILM Cellular Dynamics and Opsis Therapeutics"}]},{"@type":"WebSite","@id":"https:\/\/www.bluerocktx.com\/#website","url":"https:\/\/www.bluerocktx.com\/","name":"BlueRock Therapeutics LP","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.bluerocktx.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.bluerocktx.com\/#\/schema\/person\/7bce67a9ee8dcf888329288a28761057","name":"BlueRock Therapeutics","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.bluerocktx.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/154b53ac9f1feafa6f14d0efa17a4fdb?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/154b53ac9f1feafa6f14d0efa17a4fdb?s=96&d=mm&r=g","caption":"BlueRock Therapeutics"}}]}},"_links":{"self":[{"href":"https:\/\/www.bluerocktx.com\/wp-json\/wp\/v2\/posts\/8831"}],"collection":[{"href":"https:\/\/www.bluerocktx.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.bluerocktx.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.bluerocktx.com\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.bluerocktx.com\/wp-json\/wp\/v2\/comments?post=8831"}],"version-history":[{"count":3,"href":"https:\/\/www.bluerocktx.com\/wp-json\/wp\/v2\/posts\/8831\/revisions"}],"predecessor-version":[{"id":8903,"href":"https:\/\/www.bluerocktx.com\/wp-json\/wp\/v2\/posts\/8831\/revisions\/8903"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.bluerocktx.com\/wp-json\/wp\/v2\/media\/8835"}],"wp:attachment":[{"href":"https:\/\/www.bluerocktx.com\/wp-json\/wp\/v2\/media?parent=8831"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.bluerocktx.com\/wp-json\/wp\/v2\/categories?post=8831"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.bluerocktx.com\/wp-json\/wp\/v2\/tags?post=8831"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}